PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) CEO Matthew B. Klein sold 3,361 shares of PTC Therapeutics stock in a transaction on Friday, April 19th. The stock was sold at an average price of $24.89, for a total transaction of $83,655.29. Following the completion of the transaction, the chief executive officer now directly owns 225,807 shares of the company’s stock, valued at approximately $5,620,336.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
PTC Therapeutics Trading Down 0.8 %
PTC Therapeutics stock opened at $25.21 on Thursday. PTC Therapeutics, Inc. has a 1-year low of $17.53 and a 1-year high of $59.84. The firm’s fifty day simple moving average is $28.11 and its 200-day simple moving average is $25.74. The company has a market capitalization of $1.93 billion, a P/E ratio of -3.02 and a beta of 0.67.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.53). The business had revenue of $307.06 million during the quarter, compared to the consensus estimate of $315.90 million. On average, equities research analysts predict that PTC Therapeutics, Inc. will post -5.94 earnings per share for the current year.
Institutional Trading of PTC Therapeutics
Wall Street Analyst Weigh In
Several research analysts have recently commented on PTCT shares. Jefferies Financial Group lifted their price target on shares of PTC Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. TD Cowen reduced their target price on shares of PTC Therapeutics from $32.00 to $30.00 and set a “market perform” rating for the company in a research note on Friday, March 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of PTC Therapeutics in a research note on Friday, April 12th. Finally, Royal Bank of Canada lifted their target price on PTC Therapeutics from $22.00 to $28.00 and gave the stock a “sector perform” rating in a report on Friday, March 1st. Five research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $33.53.
Get Our Latest Research Report on PTCT
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Featured Articles
- Five stocks we like better than PTC Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Invest in the FAANG Stocks
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.